weeks first our third today. a and our and lot. the Nick front, on accomplished the in everyone. time In quarter. am the achievement afternoon the the quarter call fourth proud of I you, particular to taking few appreciate clinical good We have you join of we Thank
areas of study we I goals clinically to the the Phase in then X studies studies the and in will On remarks the of studies accomplished very year developed Phase call, have press proud in the the Ashish to to I These end, to have initiation overview. study to we X X initiations have by study this three initiate focus am the major underway my Phase this mainly by our patient for pipeline Once our across soon. the release more important very weeks, one execution financial we our ongoing morning, today’s pipeline. start With will give X on point. the our we of we of one announced issued coming are NYX-XXX year of needs. us plan now team all significant and advantage get will
neuropathy, study. jump Now, announced XXX-patient details we today. the studies X initiated In Phase let’s the a painful peripheral diabetic of into we earlier
United States. the longer a We have on effect our of study robust in who approximately prior Based DPN. enrolling duration patients, of are DPN painful showing the had are advanced across data sites, study all the we XX conducting patients them from in
XX a of evaluating milligrams We design. versus are daily dosing in NYX-XXXX placebo parallel of
with the readily able were these a the average during Hence, And XX-week from rating in the the who study be change to in for is study, the while neuropathic from greater patients we to is Phase registration not we patients are daily taking not on over study study a separation typical concomitant saw endpoint as suggesting allowing on primary placebo hindrance it baseline will endpoint recruit scale. a we patients pain were a concomitant this be Importantly, analgesic consistent XX-point not enrollments. medication medication. pain. prior X The patient-reported a using the period studies is in primary numeric endpoint
So the for data from this development. late be highly study should informative stage
XXXX. symptoms than readout XX secondary weeks, this also extending previous our not very enrollment Based endpoints the expect as weeks or a evaluating to we in patients experience, disease XXXX study. design to allowing analgesics, past in X Other this in from We focusing advanced in with other similar study study concomitant is indication. are late and on early on our
In the study study fibromyalgia, that the design with we XXX we DPN is comparable went patient initiated to just a through.
the a study XX-week daily in study We clinical the sites. period is The many from are primary same in change NIS. on of the endpoint baseline average using the over pain
We are symptoms secondary of other also endpoint. looking fibromyalgia as at several
allowing difference not arms study use the The additional and primary compared fibromyalgia is DPN concomitant three are therefore analgesic the to medications. this has in rather two XXX of study that We than patients. study
not Given designed ranging do robust daily two readout dose fibromyalgia this neuro-imaging in half dose biomarker enrolling milligrams we did the that in study NYX-XXXX the Therefore, study. in levels, in across our study, are evaluate patients placebo. compared With to first study, evaluating fibromyalgia prior XXXX, a of XXX DPN. XX their later dosing we follow-up to was milligrams we of than bit more and expect to optimally
subscale. stress as data studies Phase XXX ongoing disorder, and endpoint is our NYX-XXX study primary in placebo discuss NYX-XXX, therapy project study development the PTSD. patients in X for of first which PTSD. from with evaluating half which in its or patients in Enrollment of XXXX, briefly assesses The now multiple with posttraumatic a Let’s the is reporting versus domains symptomatic the the CAPS-X across approximately is the second PTSD
help clinical in symptomatic inform the and of very us characterize with are feature in each NYX-XXX these effects efficacy domains the next in which the steps interested We will development.
the which touch impairment. And treatment on in for of now, let’s cognitive development NYX-XXX is
Parkinson’s impairment cusp We X evaluate mild a with disease. efficacy of of with the that study associated will and its are Phase patients NYX-XXX on initiating safety in cognitive
one this look compound, with could study outstanding shift Parkinson’s disease. in been with it of the data further initiated. paradigm NYX-XXX to our about details once the believe has providing a on forward excited true we each is this are our exception. represent We We cognitive associated programs treatment on preclinical impairment and Based the of no
In call. important to since across progress I to other last our our pipeline, highlights few want the mention addition
I most First, the position very appointed. Rachel highest our Deputy pleased that the Dr. Commissioner, Dr. am as Sherman Directors. for at joined years served Principal politically agency’s Sherman not of XX Board FDA recently
preclinical posters team publications work I accomplished Second, our highlights the our times remarkable of that we these to And that multiple the have very leading proud platform. underpins foundational and am publications.
The NYX-XXXX study was reported patient effects as Rheumatology the our biomarkers of presentation website. from were and today presented the data at fibromyalgia is American on Third, in the imaging meeting evaluating positive the Annual result available and our X symptoms accepted at of Atlanta late-breaking Phase on College Meeting. a
will the Ashish. to now turn With over call I that,
